Novo Nordisk's Obesity Drug Wegovy Wins India Approval to Fight Silent Fatty Liver Killer
The approval expands Wegovy’s use beyond weight management as Novo Nordisk seeks a share of India’s fast-growing obesity-drug market.
- On Friday, India's Central Drugs Standard Control Organisation approved Novo Nordisk's Wegovy for MASH treatment, making it the first GLP-1 RA authorized in India for this serious liver condition.
- MASH develops from excess liver fat, causing chronic inflammation and potential liver damage. Novo Nordisk India claims about two in three people in India have fatty liver disease, signaling a vast patient population.
- The ESSENCE trial randomized 1,197 participants to receive semaglutide 2.4 mg or placebo for 240 weeks, demonstrating resolution of steatohepatitis in 63% of patients and reduction in liver fibrosis in 37%.
- Novo faces competition in India's obesity-drug market from Eli Lilly's Mounjaro and generic semaglutide products from Sun Pharma and Dr. Reddy's, having sold about 76,000 units of Wegovy in the first half of 2026.
- The approval provides doctors a new treatment option for patients at risk of MASH while addressing related heart and metabolic diseases, intended for adults with moderate to advanced liver fibrosis alongside lifestyle modifications.
12 Articles
12 Articles
India approves Novo Nordisk’s weight loss drug Wegovy for fatty liver disease
The Central Drugs Standard Control Organization (CDSCO) has approved Danish major Novo Nordisk’s weight loss drug Wegovy (semaglutide injection 2.4 mg) for a new indication — fatty liver disease.
India approves Novo Nordisk's obesity drug Wegovy for fatty liver disease
The Economic Times
Times of IndiaNovo Nordisk's obesity drug Wegovy wins India approval to fight silent fatty liver killer
India's drug regulator approved Novo Nordisk's Wegovy for MASH treatment. This drug targets a serious progressive form of fatty liver disease. The approval follows a committee recommendation for adults with moderate to advanced liver fibrosis. Wegovy, containing semaglutide, was previously approved for chronic weight management. This marks a significant expansion for the blockbuster obesity drug in India.
India Approves Novo Nordisk's Wegovy for Fatty Liver Disease Treatment
India’s drug regulator has approved Novo Nordisk’s obesity drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The approval covers the 2.4 mg semaglutide injection and marks another significant milestone for the blockbuster drug, which is already approved in India for chronic weight management. MASH develops due to excessive fat buildup in the liver, leading to inflamma…
Coverage Details
Bias Distribution
- 43% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
